



PRESS RELEASE: PARIS March 5, 2013: Bio-Modeling Systems recognized for the second time as a major contributor to Systems Medicine by the European Commission's DG Research.

We are very pleased to announce that Dr. François Iris, CSO of BMSystems is invited to contribute to the experts panel discussions at the 1st «Coordinating Actions Systems-Medicine" stakeholders conference supported by the European Commission DG research during Bio-Vision, the world life sciences forum in Lyon (March, 24-26, 2013).

Since its first contribution to the scientific workshop "From Systems Biology to Systems Medicine"* in 2010, organized by the European Commission DG Research, BMSystems started a major **collaborative systems medicine program (DECIUS™)** on the identification of **chronic anxiety mechanisms** that has delivered its first promising results which will be formally presented in May in Germany.

In the meantime, we shall be happy to have the opportunity to meet you during the BioVison conference in Lyon or on [LinkedIn](#), should we not be already linked.

Do not hesitate to share this information with colleagues interested by the topic.

Best regards

Manuel Gea,
Co-founder & CEO BIO-MODELING SYSTEMS
Heuristic Systems Biology
Paris, France +33683061272
manuel.gea@bmsystems.net
www.bmsystems.net
<http://www.linkedin.com/pub/manuel-gea/0/360/22b>

About Bio-Modeling Systems (or BMSystems)

Bio-Modeling Systems, an innovative company founded in 2004 and profitable since 2006, is the first and, to date, the only company that succeeded to create in-silico Heuristic models validated in-vivo. BMSystems models, built by its biologists using an integrated IT solution called CADI™ (Computer Assisted Deductive Integration) protected by industrial secrets, bring about the discovery of new mechanisms and describe the biological phenomena involved in pathological states to explain the cause of certain diseases, identify and select predictive biomarkers, offer new combinations of molecules and / or new therapeutic strategies, etc. ...

Bio-Modeling Systems is the promoter of the "Mechanism-based Medicine"™ concept. Despite huge investments, the pharmaceutical industry is hampered by a dramatically low and still declining R & D success rate. BMSystems has repeatedly shown that biomedical research based on "Mechanism-based Medicine"™ can be greatly simplified because it becomes explanatory and capable of quickly providing innovative therapies that consist in new combinations of existing molecules and are functionally better suited to patients profiles. This result in decreased short-term risks associated with therapeutic developments,

giving new life to clinically well characterized molecules, while leaving open the medium-term potential for the development of novel molecules.

BMSystems is particularly active in infectious diseases, oncology, neurology, psychiatry, dermatology and metabolic diseases, successfully completing programs that have led to patents and the creation of new companies implementing these patents:

- TAPE: WO/2008/093010 - December 2006.
- AB-ACCUS: WO/2008/093009 - December 2006.
- RPh: PCT/FR2010/050796 – May 2009.
- CNS: WO/2010/029131 (psychiatric disorders) - September, 2008, filed with CEA Life Sciences.

What BMSystems already did for itself: 5 publications, 4 patents, 1 therapeutic spin-off (Pherecydes-Pharma/Bacterial infections), 1 exclusive out license (WO/2010/029131 CAE/BMSystems) to a CEA life Sciences' spin-off.

What we can do for ourselves, we can also do for your company:

- Disease understanding / redefinition.
- New therapeutic strategies
- New associations of existing molecules (other indications, generics).
- Identification / selection of pertinent predictive Biomarkers.
- R&D programs evaluation.
- Drug (re) positioning / (re)profiling / rescue.

*[Scientific workshop "From Systems Biology to Systems Medicine"](#) in 2010 organized by the European Commission DG Research.

For more information and access to presentations and publications: www.bmsystems.net